Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

NCT06655246 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT06655246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06655246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2025
Completion date
December 31, 2028
Enrollment
157 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal cancer, gastrointestinal stromal cell tumors, gastrointestinal stromal neoplasm, gastrointestinal stromal tumor (gist), gastrointestinal stromal tumor, malignant